CL2016000734A1 - Receptor de antigeno quimerico - Google Patents
Receptor de antigeno quimericoInfo
- Publication number
- CL2016000734A1 CL2016000734A1 CL2016000734A CL2016000734A CL2016000734A1 CL 2016000734 A1 CL2016000734 A1 CL 2016000734A1 CL 2016000734 A CL2016000734 A CL 2016000734A CL 2016000734 A CL2016000734 A CL 2016000734A CL 2016000734 A1 CL2016000734 A1 CL 2016000734A1
- Authority
- CL
- Chile
- Prior art keywords
- cell
- vector
- domain
- chimeric
- receptor
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 abstract 3
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 108700010039 chimeric receptor Proteins 0.000 abstract 3
- 108010065323 Tumor Necrosis Factor Ligand Superfamily Member 13 Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000000822 natural killer cell Anatomy 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000005754 cellular signaling Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000004180 plasmocyte Anatomy 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Receptor antigénico quimérico que se une al antígeno de maduración de células B (BCMA) y que comprende i) un dominio de unión a BCMA que comprende al menos parte de un ligando inductor de proliferación (APRIL); ii) un dominio espaciador; iii) un dominio transmembrana; y iv) un dominio intracelular de señalización de células T. Ácido nucleico que codifica el receptor quimérico reivindicado y vector que comprende dicho ácido nucleico. Célula T o una célula NK que expresa el receptor quimérico reivindicado. Método para generar una célula T o NK que expresa el receptor quimérico. Composición farmacéutica que comprende el vector o la célula reivindicada además de un portador farmacéuticamente aceptable. Uso del vector o las células reivindicadas para la preparación de un medicamento para tratar desórdenes asociados con células plasmáticas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1317929.6A GB201317929D0 (en) | 2013-10-10 | 2013-10-10 | Chimeric antigen receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016000734A1 true CL2016000734A1 (es) | 2017-05-19 |
Family
ID=49679854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016000734A CL2016000734A1 (es) | 2013-10-10 | 2016-03-30 | Receptor de antigeno quimerico |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10160794B2 (es) |
| EP (1) | EP3055326B1 (es) |
| JP (2) | JP6632073B2 (es) |
| KR (1) | KR20160067177A (es) |
| CN (1) | CN105658671B (es) |
| AU (1) | AU2014333564B2 (es) |
| BR (1) | BR112016007805A2 (es) |
| CA (1) | CA2926560A1 (es) |
| CL (1) | CL2016000734A1 (es) |
| ES (1) | ES2918626T3 (es) |
| GB (1) | GB201317929D0 (es) |
| HK (1) | HK1222186A1 (es) |
| IL (1) | IL244784A0 (es) |
| MX (1) | MX2016004362A (es) |
| RU (2) | RU2684713C2 (es) |
| SG (1) | SG11201602414SA (es) |
| WO (1) | WO2015052538A1 (es) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
| US11879016B2 (en) | 2014-03-06 | 2024-01-23 | Autolus Limited | Chimeric antigen receptor |
| US11885807B2 (en) | 2014-03-05 | 2024-01-30 | Autolus Limited | Method for depleting malignant T-cells |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201317929D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| GB201317928D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
| AU2015221933B2 (en) | 2014-02-27 | 2019-09-12 | Autolus Limited | APRIL variants |
| JP6698546B2 (ja) | 2014-04-14 | 2020-05-27 | セレクティスＣｅｌｌｅｃｔｉｓ | 癌免疫療法のためのｂｃｍａ（ｃｄ２６９）特異的キメラ抗原受容体 |
| CN107531801B (zh) | 2015-01-26 | 2021-11-12 | 塞勒克提斯公司 | 用于分选/清除工程化的免疫细胞的mAb驱动的嵌合抗原受体系统 |
| KR102349475B1 (ko) | 2015-04-13 | 2022-01-11 | 화이자 인코포레이티드 | B-세포 성숙 항원을 표적화하는 키메라 항원 수용체 |
| GB201507115D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
| GB201507111D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic acid construct |
| GB201507108D0 (en) | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic acid construct |
| IL303905A (en) | 2015-05-18 | 2023-08-01 | Tcr2 Therapeutics Inc | Compositions and methods for TCR programming using fusion proteins |
| MA42895A (fr) * | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
| AU2016302881B2 (en) | 2015-08-03 | 2022-09-15 | Bristol-Myers Squibb Company | Monoclonal antibodies against BCMA |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| US11090334B2 (en) | 2016-01-29 | 2021-08-17 | Med Manor Organics (P) Ltd. | Chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof |
| BR112018073673A2 (pt) | 2016-05-20 | 2019-02-26 | Eli Lilly And Company | terapia de combinação com inibidores de notch e de pd-1 ou pd-l1 |
| CN109641012A (zh) * | 2016-06-07 | 2019-04-16 | 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 | 与bcma结合的嵌合抗原受体和car-t细胞 |
| AU2017306432A1 (en) | 2016-08-02 | 2019-03-21 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| EP3848392A1 (en) | 2016-10-07 | 2021-07-14 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| AU2017353427A1 (en) | 2016-11-02 | 2019-05-16 | Bristol-Myers Squibb Company | Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma |
| US20190352409A1 (en) * | 2016-11-11 | 2019-11-21 | Autolus Limited | Chimeric antigen receptor |
| EP3544996A2 (en) | 2016-11-22 | 2019-10-02 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| AU2018207300B2 (en) * | 2017-01-10 | 2023-08-24 | The General Hospital Corporation | T cells expressing a chimeric antigen receptor |
| SG11201907580SA (en) * | 2017-02-17 | 2019-09-27 | Hutchinson Fred Cancer Res | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| GB201709508D0 (en) * | 2017-06-15 | 2017-08-02 | Autolus Ltd | Chimeric antigen receptor |
| CA3071495A1 (en) * | 2017-08-02 | 2019-02-07 | Autolus Limited | Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed |
| GB201716728D0 (en) | 2017-10-12 | 2017-11-29 | Autolus Ltd | Cell |
| WO2019089982A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
| EP3706754A1 (en) * | 2017-11-06 | 2020-09-16 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
| CN109971715A (zh) * | 2017-12-28 | 2019-07-05 | 深圳华大生命科学研究院 | 一种扩增特异性car-t细胞的培养方法 |
| AU2019206573B2 (en) * | 2018-01-10 | 2024-06-06 | The General Hospital Corporation | Immune cells expressing a chimeric antigen receptor |
| TWI728308B (zh) * | 2018-02-01 | 2021-05-21 | 大陸商南京馴鹿醫療技術有限公司 | 一種結合ｂｃｍａ的嵌合抗原受體（ｃａｒ）及其應用 |
| WO2019180724A1 (en) * | 2018-03-23 | 2019-09-26 | Gavish-Galilee Bio Applications Ltd. | Genetically reprogrammed tregs expressing membrane-bound il-10 |
| GB201807693D0 (en) | 2018-05-11 | 2018-06-27 | Autolus Ltd | Cell |
| CU20200089A7 (es) | 2018-06-01 | 2021-07-02 | Novartis Ag | Moléculas de unión contra bcma |
| CA3103610A1 (en) | 2018-06-12 | 2019-12-19 | The Regents Of The University Of California | Single-chain bispecific chimeric antigen receptors for the treatment of cancer |
| US12049510B2 (en) | 2018-09-27 | 2024-07-30 | Autolus Limited | Chimeric antigen receptor |
| PE20211058A1 (es) | 2018-11-01 | 2021-06-07 | Juno Therapeutics Inc | Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d) |
| EP3893923A2 (en) | 2018-12-14 | 2021-10-20 | Autolus Limited | Cell |
| GB201904160D0 (en) | 2019-03-26 | 2019-05-08 | Autolus Ltd | Cell |
| WO2020172643A2 (en) * | 2019-02-21 | 2020-08-27 | Luk John M | Artificial immunosurveillance chimeric antigen receptor (ai-car) and cells expressing the same |
| US20220145325A1 (en) | 2019-03-08 | 2022-05-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| GB201903237D0 (en) | 2019-03-08 | 2019-04-24 | Autolus Ltd | Method |
| EP3941589A1 (en) | 2019-03-21 | 2022-01-26 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| GB201904971D0 (en) | 2019-04-08 | 2019-05-22 | Autolus Ltd | Cell |
| GB201906202D0 (en) | 2019-05-02 | 2019-06-19 | Autolus Ltd | Cell |
| WO2020224606A1 (zh) | 2019-05-07 | 2020-11-12 | 亘喜生物科技（上海）有限公司 | 靶向bcma的工程化免疫细胞及其用途 |
| CN113784733B (zh) | 2019-05-07 | 2024-09-06 | 亘喜生物科技（上海）有限公司 | 靶向bcma的工程化免疫细胞及其用途 |
| CN110592015A (zh) * | 2019-09-27 | 2019-12-20 | 中国科学院西双版纳热带植物园 | 一种诱导增强cik细胞的滇重楼多糖组合物及其应用 |
| US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
| WO2024031091A2 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ294615B6 (cs) * | 1997-09-12 | 2005-02-16 | Apotech R & D Sa | Léčivo obsahující protilátky reaktivní s polypeptidovým ligandem APRIL pro léčení rakoviny |
| UA74798C2 (uk) * | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| DK1297013T3 (da) * | 2000-04-27 | 2006-12-27 | Biogen Idec Inc | Anvendelse af TACI som antitumormiddel |
| CA2419661A1 (en) * | 2000-08-15 | 2002-03-07 | Guo-Liang Yu | Neutrokine-alpha and neutrokine-alpha splice variant |
| US20030012783A1 (en) * | 2001-02-20 | 2003-01-16 | Wayne Kindsvogel | Antibodies that bind both BCMA and TACI |
| CN101683520A (zh) * | 2002-04-09 | 2010-03-31 | 比奥根艾迪克Ma公司 | 用于治疗tweak相关病症的方法 |
| AU2003270715A1 (en) * | 2002-09-19 | 2004-04-08 | Biogen Idec Ma Inc. | Improved methods for preparing highly active april ligand polypeptides |
| US7947805B2 (en) * | 2004-12-23 | 2011-05-24 | Merck Serono S.A. | BCMA polypeptides and uses thereof |
| AT503861B1 (de) * | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| US20100105136A1 (en) | 2006-10-09 | 2010-04-29 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| KR20220029757A (ko) * | 2012-04-11 | 2022-03-08 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | B-세포 성숙 항원을 표적화하는 키메라 항원 수용체 |
| CN103145849B (zh) * | 2013-02-18 | 2014-06-11 | 冯振卿 | 嵌合抗原受体及其用途 |
| GB201317929D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| AU2015221933B2 (en) * | 2014-02-27 | 2019-09-12 | Autolus Limited | APRIL variants |
| US20190352409A1 (en) | 2016-11-11 | 2019-11-21 | Autolus Limited | Chimeric antigen receptor |
| GB201709508D0 (en) | 2017-06-15 | 2017-08-02 | Autolus Ltd | Chimeric antigen receptor |
| AU2019206573B2 (en) * | 2018-01-10 | 2024-06-06 | The General Hospital Corporation | Immune cells expressing a chimeric antigen receptor |
-
2013
- 2013-10-10 GB GBGB1317929.6A patent/GB201317929D0/en not_active Ceased
-
2014
- 2014-10-10 EP EP14784368.4A patent/EP3055326B1/en active Active
- 2014-10-10 JP JP2016521314A patent/JP6632073B2/ja active Active
- 2014-10-10 WO PCT/GB2014/053058 patent/WO2015052538A1/en active Application Filing
- 2014-10-10 RU RU2016117383A patent/RU2684713C2/ru not_active IP Right Cessation
- 2014-10-10 AU AU2014333564A patent/AU2014333564B2/en not_active Ceased
- 2014-10-10 KR KR1020167012121A patent/KR20160067177A/ko not_active Application Discontinuation
- 2014-10-10 CA CA2926560A patent/CA2926560A1/en not_active Abandoned
- 2014-10-10 ES ES14784368T patent/ES2918626T3/es active Active
- 2014-10-10 RU RU2019102382A patent/RU2019102382A/ru not_active Application Discontinuation
- 2014-10-10 MX MX2016004362A patent/MX2016004362A/es unknown
- 2014-10-10 CN CN201480055657.6A patent/CN105658671B/zh active Active
- 2014-10-10 BR BR112016007805A patent/BR112016007805A2/pt not_active Application Discontinuation
- 2014-10-10 SG SG11201602414SA patent/SG11201602414SA/en unknown
- 2014-10-10 US US15/028,064 patent/US10160794B2/en active Active
-
2016
- 2016-03-28 IL IL244784A patent/IL244784A0/en unknown
- 2016-03-30 CL CL2016000734A patent/CL2016000734A1/es unknown
- 2016-09-01 HK HK16110442.5A patent/HK1222186A1/zh unknown
-
2018
- 2018-10-17 US US16/162,747 patent/US10919951B2/en active Active
-
2019
- 2019-01-10 JP JP2019002499A patent/JP2019052190A/ja not_active Withdrawn
-
2020
- 2020-10-22 US US17/077,782 patent/US20210101959A1/en not_active Abandoned
-
2023
- 2023-05-22 US US18/321,400 patent/US20240076352A1/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11885807B2 (en) | 2014-03-05 | 2024-01-30 | Autolus Limited | Method for depleting malignant T-cells |
| US11885806B2 (en) | 2014-03-05 | 2024-01-30 | Autolus Limited | Method for depleting malignant T-cells |
| US11982673B2 (en) | 2014-03-05 | 2024-05-14 | Autolus Limited | Methods |
| US11982672B2 (en) | 2014-03-05 | 2024-05-14 | Autolus Limited | Methods |
| US11879016B2 (en) | 2014-03-06 | 2024-01-23 | Autolus Limited | Chimeric antigen receptor |
| US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
Also Published As
| Publication number | Publication date |
|---|---|
| US20160237139A1 (en) | 2016-08-18 |
| BR112016007805A2 (pt) | 2017-12-05 |
| CA2926560A1 (en) | 2015-04-16 |
| AU2014333564A1 (en) | 2016-04-28 |
| US10160794B2 (en) | 2018-12-25 |
| WO2015052538A1 (en) | 2015-04-16 |
| US20210101959A1 (en) | 2021-04-08 |
| KR20160067177A (ko) | 2016-06-13 |
| GB201317929D0 (en) | 2013-11-27 |
| MX2016004362A (es) | 2016-10-13 |
| RU2016117383A (ru) | 2017-11-15 |
| JP2019052190A (ja) | 2019-04-04 |
| US20190100571A1 (en) | 2019-04-04 |
| SG11201602414SA (en) | 2016-04-28 |
| US20240076352A1 (en) | 2024-03-07 |
| EP3055326A1 (en) | 2016-08-17 |
| EP3055326B1 (en) | 2022-04-20 |
| JP2016538830A (ja) | 2016-12-15 |
| AU2014333564B2 (en) | 2018-09-27 |
| RU2019102382A (ru) | 2019-02-22 |
| RU2016117383A3 (es) | 2018-05-22 |
| ES2918626T3 (es) | 2022-07-19 |
| HK1222186A1 (zh) | 2017-06-23 |
| IL244784A0 (en) | 2016-04-21 |
| CN105658671A (zh) | 2016-06-08 |
| CN105658671B (zh) | 2021-08-27 |
| JP6632073B2 (ja) | 2020-01-15 |
| RU2684713C2 (ru) | 2019-04-11 |
| US10919951B2 (en) | 2021-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016000734A1 (es) | Receptor de antigeno quimerico | |
| CR20150664A (es) | Moduladores de los receptores de estrógeno y sus usos | |
| CL2016000468A1 (es) | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso. | |
| EA201891022A1 (ru) | Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела | |
| CL2016002269A1 (es) | Moduladores alostéricos del núcleo proteico de la hepatitis b. | |
| CL2018000515A1 (es) | Virus de la enfermedad de newcastle y usos de los mismos (divisional sol. 2532-2015) | |
| BR112019012354A2 (pt) | anticorpos apenas de cadeia pesada anti-bcma | |
| AR102554A1 (es) | Receptores quiméricos de antígeno anti-cldn y métodos de uso | |
| BR112014024494A2 (pt) | dosagem e administração de anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos | |
| CL2016002004A1 (es) | Anticuerpos anti-jagged1 y métodos de uso | |
| PH12015501846A1 (en) | Novel antibody conjugates and uses thereof | |
| AR090909A1 (es) | Antagonistas de st2l y metodos de uso | |
| AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
| TN2014000438A1 (en) | Anti-fcrn antibodies | |
| MX2015013899A (es) | Anticuerpos biespecificos especificos para fap y dr5, anticuerpos especificos para dr5 y metodos de utilizacion. | |
| CL2015000256A1 (es) | Compuestos heteroaromáticos, inhibidores de btk, composicion farmaceutica que los comprende y uso en enfermedades tales como artritis reumatoide, lupus, entre otras. | |
| EA201491161A1 (ru) | Фторированные модуляторы рецепторов эстрогенов и их применение | |
| EA201991207A1 (ru) | Новые агонисты tnfr и их применение | |
| AR128816A2 (es) | Formas de dosificación farmacéutica de perlas de cisteamina | |
| CL2017000506A1 (es) | Nuevos anticuerpos anti-mfi2 y metodos de uso | |
| BR112016002401A8 (pt) | Métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
| UY36678A (es) | Anticuerpos anti-fcrn. | |
| MX2017003691A (es) | Metodos para tratar lupus eritematoso sistemico usando un anticuerpo de dominio dirigido contra cd28. | |
| PH12016500753B1 (en) | Antibodies specific to fcrn | |
| MX2017003216A (es) | Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica. |